MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,116K
Free Cash flow
-$70,054K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Issuance of common stock under t...
Proceeds from long-term debt, ne...
Others
Negative Cash Flow Breakdown
Net loss
Purchase of marketable securitie...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-72,936
-68,760
19,397
-56,876
Stock-based compensation expense
5,884
4,453
5,553
4,519
Vesting of common stock warrants in return for services
-
-
0
-
Change in fair value of derivative liability
14
12
13
11
Depreciation and amortization
1,280
1,269
1,216
1,261
Loss on disposal of property and equipment
-43
-
-
-
Amortization of right-of-use assets
809
786
764
742
Net accretion of discount on marketable securities
990
1,134
1,147
1,154
Prepaid expenses and other current assets
6,532
3,993
3,165
-2,748
Other non-current assets
-18
670
-192
-10
Accounts payable
-4,058
3,533
4,296
-1,837
Accrued and other liabilities
6,544
-4,123
2,372
4,982
Deferred revenue
830
1,380
-90
-90
Operating lease liabilities
-905
-878
-850
-814
Net cash used in operating activities
-69,999
-68,125
28,551
-46,498
Purchase of marketable securities
62,036
33,519
178,100
15,241
Maturities of marketable securities
87,646
102,396
49,183
32,928
Disposal (acquisition) of property and equipment
-
-11
-
-
Acquisition of property and equipment
55
-
-70
-91
Net cash provided by investing activities
25,544
68,888
-128,847
17,778
Issuance of common stock upon exercise of stock options and vesting of rsus
-
-
984
-
Issuance of common stock under the offering program, net of issuance costs-Public Offering
-
-
0
-
Issuance of common stock under the offering program, net of issuance costs-Underwritten Offering
-
-
93,540
-
Issuance of common stock upon exercise of stock options
111
1,674
-
-
Issuance of common stock upon exercise of stock options and warrants
-
-
-
116
Issuance of common stock under the atm offering program, net of issuance costs
21,844
9,810
9,683
-
Issuance of common stock - 2020 espp
1,125
-
393
0
Issuance of common stock under stock purchase agreement
-
-
7,500
-
Proceeds from long-term debt, net of discount and issuance costs
19,259
-
-
-
Net cash provided by financing activities
42,339
11,484
111,982
116
Net increase (decrease) in cash and cash equivalents
-2,116
12,247
11,686
-28,604
Cash and cash equivalents, beginning of period
72,488
60,241
48,555
149,336
Cash and cash equivalents, end of period
70,372
72,488
60,241
48,555
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of common stock
under the atm offering...
$21,844K
Proceeds from long-term
debt, net of discount...
$19,259K
Issuance of common stock -
2020 espp
$1,125K
(30.81%↑ Y/Y)
Issuance of common stock
upon exercise of...
$111K
Maturities of marketable
securities
$87,646K
(-67.33%↓ Y/Y)
Net cash provided by
financing activities
$42,339K
(4811.72%↑ Y/Y)
Net cash provided by
investing activities
$25,544K
(41.16%↑ Y/Y)
Canceled cashflow
$62,091K
Net increase
(decrease) in cash and cash...
-$2,116K
(97.07%↑ Y/Y)
Canceled cashflow
$67,883K
Accrued and other
liabilities
$6,544K
(720.05%↑ Y/Y)
Stock-based compensation
expense
$5,884K
(-50.74%↓ Y/Y)
Depreciation and
amortization
$1,280K
(-42.26%↓ Y/Y)
Deferred revenue
$830K
(2962.07%↑ Y/Y)
Amortization of right-of-use
assets
$809K
(-43.23%↓ Y/Y)
Loss on disposal of
property and equipment
-$43K
Other non-current
assets
-$18K
(-100.35%↓ Y/Y)
Change in fair value of
derivative liability
$14K
(118.42%↑ Y/Y)
Purchase of marketable
securities
$62,036K
(-75.13%↓ Y/Y)
Acquisition of property and
equipment
$55K
(-92.11%↓ Y/Y)
Net cash used in
operating activities
-$69,999K
(23.19%↑ Y/Y)
Canceled cashflow
$15,422K
Net loss
-$72,936K
(28.93%↑ Y/Y)
Prepaid expenses and
other current assets
$6,532K
(93214.29%↑ Y/Y)
Accounts payable
-$4,058K
(-194.07%↓ Y/Y)
Net accretion of
discount on marketable...
$990K
(-59.31%↓ Y/Y)
Operating lease
liabilities
-$905K
(40.81%↑ Y/Y)
Buy us a coffee
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)